KRRO NASDAQ
Korro Bio, Inc.
1W: +18.9%
1M: +3.5%
3M: +31.1%
YTD: +71.5%
1Y: -61.1%
3Y: -38.5%
5Y: -96.5%
$13.81
+0.75 (+5.74%)
Weekly Expected Move ±9.5%
$11
$12
$14
$15
$16
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.1M
Congress—
ETF Holdings—
Key Statistics
Market Cap$137.5M
52W Range5.204-55.89
Volume197,973
Avg Volume163,087
Beta2.25
Dividend—
Analyst Ratings
Company Info
CEORam Aiyar
Employees57
SectorHealthcare
IndustryBiotechnology
IPO Date2019-10-03
Websitekorrobio.com
60 First Street
Cambridge, MA 02141
US
Cambridge, MA 02141
US
781-315-4600
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Latest News
BlackRock Inc. Takes Position in Korro Bio, Inc. $KRRO
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of “Moderate Buy” by Analysts
All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy
Strength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength?
Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Dolan Oliver | S-Sale | 6 | $13.60 | 2026-09-09 |
| Dolan Oliver | S-Sale | 7,347 | $13.51 | 2026-09-08 |
| FORMELA JEAN FRANCOI | S-Sale | 249 | $13.96 | 2026-08-26 |
| FORMELA JEAN FRANCOI | S-Sale | 51 | $13.96 | 2026-08-26 |
| FORMELA JEAN FRANCOI | S-Sale | 23,584 | $14.00 | 2026-08-19 |